【正文】 幾本關(guān)于現(xiàn)代英國的書，很有見地。在書中，馬爾描述了女王和她強(qiáng)烈的使命感：女王是“受到了上帝召喚”，要將自己的生命獻(xiàn)給民眾。這個想法非常明智，但是這過度夸大了大多數(shù)英國人對現(xiàn)行體制的擔(dān)心。Mr Marr palpably likes the queen, whether for touring the country to greet and thank peoplemostly ignored by “London power brokers”, or for relaxing when her work is done with “aglass of something cheerful”.Yet liking is not really the Mr Marr s words, there isonly a little space, though “an interesting space”, between the queen and the woman wholives her calling gives her “is what she does”.能感覺的出來，馬爾是欣賞女王的。女王應(yīng)有的使命感賦予了她意義。所見即所信。and is trying to instil a valuesbased culture, in which employees can be trusted to do theright thing because they know what the firm stands ，沃爾瑪正嘗試逐漸培養(yǎng)一種以價值觀為基礎(chǔ)的公司文化，在這種文化中，員工了解公司的主張，所以能夠得到公司的信任，去做他們認(rèn)為正確的事情。Nearly every big firm claims to be building a more caring and ethical 幾乎每一家大型企業(yè)都宣稱自身正在發(fā)展更為關(guān)懷體貼、合乎道德的企業(yè)文化。The largest category, 54%, saw their employer s culture as topdown, but with skilledleadership, lots of rules and a mix of carrots and sticks, which Mr Seidman calls ，即有54%的人認(rèn)為其公司文化自上而下型的，但公司的領(lǐng)導(dǎo)也有技巧可言，只是規(guī)則繁多并存在軟硬兼施的手段，塞德曼先生稱這種為 知情服從型。Yet only a quarter of those in the blindobedience firms said they were likely to blow thewhistle, pared with over 90% in selfgoverning ，在盲目服從型企業(yè)中只有約四分之一的員工說他們可能會揭發(fā)這種行為，而在自我管理型企業(yè)中卻有90%的員工會進(jìn)行揭發(fā)。Tragiically, the study found that bosses often believe their own guff, even if theirunderlings do ，研究還發(fā)現(xiàn)老板們時常對自己瞎掰的那一套信以為真，即便員工們不以為然?？射J教育官網(wǎng)Likewise, 41% of bosses say their firm rewards performance based on values rather thanmerely on financial ，41%的老板稱其公司對績效的獎勵是建基于價值觀之上的，而不僅是業(yè)績。Find a way to battle the bulge and a huge profit might be ，說必定就此大賺一筆。However, the pill s longawaited final approval may not e until April, if at 但是，如果獲得批準(zhǔn)，該藥品的漫長的最終肯定直到四月份才會到來。This is not for lack of 。Allergan, best known for selling Botox, has tried to use its LapBand to tap the ，嘗試用產(chǎn)品LapBand打入減肥市場。Some patients have had bands removed because they slipped or proved ，因?yàn)槭鴰Т蚧蛘邲]有效果。There is some scepticism about his chances of success: The fact that banding is not as goodas bypass has been known by everybody except the PR firms for the band, says LeeKaplan, director of the Weight Centre at Massachusetts General ：“事實(shí)上使用束帶不必胃繞道手術(shù)好，所有人都知道，除了束帶的公關(guān)公司，”馬薩諸塞州中心醫(yī)院體重中心主任Lee Kaplan如是說。The FDA rejected Vivus s Qnexa in 2010 over concerns for the safety of pregnant women andthe quickening of patients heart ，因?yàn)閾?dān)心該藥對孕婦的安全造成傷害，擔(dān)心該藥會加快患者的心率。Qnexa bines two treatments that are already on the 。On November 29th America s Federal Trade Commission announced that it hadreached a draft settlement with the giant social network over allegations that it hadmisled people about its use of their personal 、濫用用戶個人信息的控訴初步達(dá)成解決方案。The regulator s findings e at a sensitive time for Facebook, which is said to be preparingfor an initial public offering next year that could value it at around $100 。Announcing the agreement, the FTC said it had found a number of cases where Facebook hadmade claims that were unfair and deceptive, and violated federal ，F(xiàn)TC說發(fā)現(xiàn)有好幾回臉譜的聲明都是 不公平，虛假并觸犯聯(lián)邦法 的，F(xiàn)or instance, it passed on personally identifiable information to advertisers, even though itsaid it would not do ，它把用戶身份信息透露給廣告商，但是嘴上卻聲稱不會做此類事情。In a blog post published the same day, Mark Zuckerberg, Facebook s boss, tried to play downthe impact of the ，臉譜老板Mark Zuckerberg在一篇博文上極力淡化這份協(xié)議的影響。Among other things, the pany will now have to seek consumers approval before itchanges the way it shares their it has agreed to an independent privacy auditevery two years for the next 20 ，在改變用戶信息共享方式前，它還必須征詢用戶的同意，并且它也同意在未來二十年里每兩年進(jìn)行一次獨(dú)立的隱私審核。The audits can be used to tweak the framework in the light of new ，這些審核有助于打破原本框架。二．Drugmakers Cliffhanger制藥企業(yè) 懸念Big Pharma struggles to protect its blockbusters as they lose patent protection大型制藥企業(yè)艱難保護(hù)著專利失效的 重磅炸彈 藥物FOR some years the big drugmakers have been dreading an approaching patent cliff —aslump in sales as the patents on their most popular pills expire or are struck down by legalchallenges, with few new potential blockbusters to take their ，大型制藥企業(yè)一直擔(dān)心 專利懸崖 出現(xiàn)——最暢銷藥品的專利到期或?qū)＠蛟V訟而中止，而市場上鮮有新的 重磅炸彈 藥物，這時企業(yè)的銷售額將會銳減。Patients and healthcare payers should reap the ，而輝瑞的收入會縮水。More important, researchbased drug firms are using a variety of tactics to make the patentcliff slope more ，以研發(fā)為基礎(chǔ)的制藥公司正使用各種方法緩沖 專利懸崖 效應(yīng)。American and European regulators are looking into these 美國和歐洲的監(jiān)管部門也開始調(diào)查這些協(xié)議。According to BernsteinResearch, under the deal between the two drugmakers Pfizer willreceive about 70% of Watson s revenues from its approved copy of ，在此交易期間，華生公司獲得立普妥的仿制權(quán)，輝瑞將獲得華生公司年收入的70%。Patients with a special discount card from Pfizer will make copayments of just $4 for a month s worth of the originalLipitor, pared with about $10 for many generic ，若使用一種特殊打折卡，通過共同支付方式，只花4美元就可以獲得一個月用量的立普妥專利藥，而其他仿制品需要花費(fèi)約10美元。Others fear that Pfizer s tactics may drive up costs for the employers who sponsor healthplans, thanks to the plexities of copayment schemes, and confuse patients lectured foryears about the merits of ，由于共同支付計(jì)劃很復(fù)雜，輝瑞的戰(zhàn)術(shù)會增加雇主門支付健康計(jì)劃的成本，也讓患者。All this may raise Pfizer s sales by nearly $500m in the first half of 2012 pared with whatthey would otherwise have been, says Tim Anderson of BernsteinResearch, with revenuesthen falling after the 180 days are Anderson認(rèn)為，所有這些舉措將使得輝瑞2012年上半年的銷售額比不采取措施時增加近5億美元，總收入在180天市場獨(dú)占期后會下降。So Ranbaxy faces not one, but two ，蘭伯西的對手是兩個，而非一個。To encourage generics makers to challenge patents on drugs, and introduce cheapercopies，為了鼓勵非專利制藥企業(yè)挑戰(zhàn)藥品專利、生產(chǎn)價錢更低的仿制藥，an American law passed in 1984 says that the first one to do so will get a 180day exclusivityperiod，美國于1984年通過一項(xiàng)法案，其中提到 第一個挑戰(zhàn)成功的仿制藥企能獲得180天市場獨(dú)占期，in which no other generics maker can sell versions of the drug in question, as Ranbaxysupposedly won with ，就像蘭伯西獲得立普妥仿制藥的生產(chǎn)權(quán)一樣。Another tactic is payfordelay , in which a drugmaker facing a legal challenge to itspatent pays its wouldbe petitor to put off introducing its cheaper 有償延遲 協(xié)議，也就是說在專利訴訟時，制藥企業(yè)會付給未來競爭對手